GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Additional Paid-In Capital

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Additional Paid-In Capital : $257.69 Mil(As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Calliditas Therapeutics AB Additional Paid-In Capital?


Calliditas Therapeutics AB's quarterly additional paid-in capital stayed the same from Jun. 2023 ($0.00 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($257.69 Mil).

Calliditas Therapeutics AB's annual additional paid-in capital declined from Dec. 2021 ($270.61 Mil) to Dec. 2022 ($249.65 Mil) but then increased from Dec. 2022 ($249.65 Mil) to Dec. 2023 ($257.69 Mil).

Calliditas Therapeutics AB Additional Paid-In Capital Historical Data

The historical data trend for Calliditas Therapeutics AB's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Calliditas Therapeutics AB Additional Paid-In Capital Chart

Calliditas Therapeutics AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 135.14 255.07 270.61 249.65 257.69

Calliditas Therapeutics AB Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 233.63 249.65 - - 257.69

Calliditas Therapeutics AB Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Calliditas Therapeutics AB Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Calliditas Therapeutics AB's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Calliditas Therapeutics AB (Calliditas Therapeutics AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Calliditas Therapeutics AB (NAS:CALT) » Definitions » Additional Paid-In Capital
Comparable Companies
OSTO:GENO OSTO:VICO OSTO:EGTX OSTO:HNSA OSTO:IBT B OSTO:FLUO OSTO:BINV OSTO:XSPRAY OSTO:ONCO OSTO:DMYD B OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
CALTX:Sweden CALTXs:UK LC8:Germany
Address
Kungsbron 1, D5, Stockholm, SWE, SE-111 22
Website
https://www.calliditas.se
Calliditas Therapeutics AB is a commercial-stage biopharma company focused on identifying, developing, and commercializing novel treatments in orphan indications, with an initial focus on renal and hepatic diseases with unmet medical needs. The company's pipeline candidate is TARPEYO medication to reduce proteinuria in IgA nephropathy.